Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies

BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRAF V600 mutations, but treatment resistance often leads to disease progression. A multi-center analysis of BRAF inhibitor resistant patient tissue samples detected genomic changes after disease progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Luebker, Stephen A., Koepsell, Scott A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478763/
https://www.ncbi.nlm.nih.gov/pubmed/31058079
http://dx.doi.org/10.3389/fonc.2019.00268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478763/
https://www.ncbi.nlm.nih.gov/pubmed/31058079
http://dx.doi.org/10.3389/fonc.2019.00268

Ejemplares similares